Reimbursement Codes effective January 1, 2012 will cover cancer patients for additional treatment options
“We are pleased that the AMA and ASTRO supported these codes for electron IORT. By approving new CPT codes for electron IORT procedures, patients will have greater access to a single, two minute, radiation treatment during surgery. These patients will benefit from a reduction of up to seven weeks of external beam radiation, also reducing the toxicity of their treatment and providing a quick return their normal lives.” said John Powers, Chief Executive Officer of IntraOp. “We anticipate that these new codes will increase patient awareness and availability of electron IORT to cancer patients throughout the United States.”IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. The IntraOp Mobetron is a patented, self-shielded, mobile, linear accelerator that allows hospitals to provide electron IORT in existing operating rooms at the time of surgery. Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Centers of excellence in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program. The Mobetron is used to effectively treat over 20 different cancer indications.For more information on IntraOp Medical Corporation, please visit www.intraopmedical.comAbout IntraOp
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
No comments:
Post a Comment